Drug Trial Radar · NCT04435652
A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.
Last checked: Nov 19, 2026Latest source record: Jun 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
492
Planned (sponsor's estimate)
Start
Jul 1, 2020
Primary completion
Apr 30, 2022
Study completion Nov 30, 2022
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who had tumor progression after first-line treatment with platinum and fluoropyrimidine doublet therapy. The study will be conducted in 2 parts.
Conditions
- Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Interventions
QL1604Drug
3mg/kg, D1,8,15,Q4w, IV infusion
Nab-paclitaxelDrug
100mg/m2, D1,8,15,Q4w, IV infusion
PaclitaxelDrug
80mg/m2, D1,8,15,Q4w, IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence and severity of adverse events (AE) and serious adverse events (SAE) according to CTCAE V5.0Time frame: Up to 90 days from last dose
- The percentages of participants discontinuing or suspending the study drug due to an AE.Time frame: Up to 90 days from last dose
- Overall survival(OS)(stage 2)Time frame: from the date of first dose until the date of death from any cause,assessed up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Cancer Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.